Board of Directors
Alastair MacCormick BSc, MCom, PhD - Chairman & Non-Executive Nominee Director.
Dr MacCormick is an experienced director with consulting and directorship experience spanning business, government, not-for-profit and university sectors in Asia, Australia, New Zealand and the United States of America.
Previously, Dean of the Business School and Professor of Management at the University of Auckland, he was later Deputy Vice Chancellor; Foundation Chairman of Connect NZ Auckland, Chairman of the AUT Technology Park Advisory Board and has extensive involvement in New Zealand's Pacific Economic Cooperation Council and APEC.
Dr MacCormick holds a number of directorships including other new venture companies with a technology focus.
Maxine Simmons MSc, NZID - Non-Executive Nominee Director.
Ms Simmons co-founded one of New Zealand's first biotechnology companies in 1983 and received the Distinguished New Zealand Biotechnologist award from the Biotechnology community for this pioneering work. She is CEO of the seed co-investment fund Cure Kids Ventures Ltd, advises early stage biotechnology ventures on commercialization and capital raising through her company BioCatalyst Ltd, and is involved in investment and review committees for the Ministry of Science and Innovation.
Previously a director of the Foundation for Research, Science and Technology and a founding director of Industry New Zealand (now New Zealand Trade and Enterprise), she is Chair of NZBIO, and is a director of the Maurice Wilkins Centre for BioDiscovery, Industrial Research Ltd and a number of life science companies.
Maxine is currently a New Zealand representative on the APEC Business Advisory Council.
Doug Wilson MB, ChB, PhD, FRACP, FRCPA – Non-Executive Nominee Director.
Dr Wilson was Senior Vice President for Medical and Regulatory Affairs for Boehringer Ingelheim Pharmaceuticals (USA) for ten years where he oversaw a team of 400, including a number of medical staff, and was responsible for over 50 parallel drug developments.
Subsequently, head of Boehringer's worldwide medical research group overseeing all research programmes and working on upward of 100 drugs, he later relocated to Ingelheim (Germany) as head of Medicine and Regulatory Affairs worldwide.
He is also Executive Chairman of ASX-listed biotech Phylogica (a drug discovery company) and is a director of Sea Dragon (a New Zealand company producing omega-3 oils by molecular distillation of fish oil).
Dr Greg Collier PhD - Non-Executive Nominee Director.
Dr Collier has more than 20 years experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialisation. He has led the planning and execution of multiple commercial transactions including in and out licensing deals and major M&A activities, and he has successfully taken a drug from discovery through to regulatory approval. Notably, Dr Collier steered ChemGenex Pharmaceuticals from a research-based company with a market capitalisation of $10M to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon for $230M.
Prior to his commercial pharmaceutical career, Dr Collier had an outstanding academic career resulting in over 150 peer reviewed publications, and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto. In 2010, Dr Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry. Dr Collier is CEO of the ASX listed biotechnology company Invion Limited.